ANKE BIO
3000098.260.36% ( +0.03 )
ANKE BIO (300009)
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection...
- Open
- 8.21
- High
- 8.32
- Low
- 8.20
- Prev. Close
- 8.23
- Volume
- 161.55K
- Turnover
- 133.62M
- Avg Price
- 8.27
- Bid/Ask Ratio
- --
- Amplitude
- 1.46%
- 52wk High
- 12.81
- Volume Ratio
- 0.50
- Turnover Ratio
- 0.97%
ANKE BIO Analyst Rating
View MoreForecast & Rating
May 7, 2026Price forecast
¥10.7830.51%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Zhitong · Oct 29, 2025 at 02:28 AM
ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next year
- Zhitong · Oct 27, 2025 at 10:33 AM
ANKE BIO released its performance for the first three quarters, with a net profit attributable to the parent company of 551 million yuan, a decrease of 6.48%
- Zhitong · Oct 26, 2025 at 07:16 PM
ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infections
- Zhitong · Oct 20, 2025 at 07:01 PM
ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting
- Zhitong · Oct 20, 2025 at 06:50 PM
ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%
- 36Kr · Sep 28, 2025 at 12:01 AM
ANKE BIO: The company's controlling shareholder does not lend the shares held to quantitative institutions
